Ann Arbor, Michigan 48109

  • Mass Lesion

Purpose:

This is a randomized study that will enroll patients scheduled for an endoscopic biopsy of a pancreas lesion to be in the heparin or saline group during the procedure. The purpose of this study is to examine the effect of blood contamination, heparin priming of the fine needle biopsies, and pass number on tumor tissue quality in fine needle biopsies. The hypothesis for this study is that fine needle biopsy tissue quality of pancreatic masses decreases with increasing pass number due to blood contamination; this blood contamination can be ameliorated with priming of the needle with an anticoagulant such as heparin.


Criteria:

Inclusion Criteria: - patients identified as having a possible solid lesion in their pancreas on radiographic imaging - scheduled for endoscopic fine needle biopsy (FNB) for clinical purposes. Exclusion Criteria: - known history of coagulopathy - history of heparin allergy - patients with evidence of vascular tumors on imaging


NCT ID:

NCT04764396


Primary Contact:

Principal Investigator
Richard Kwon, MD
University of Michigan

Eileen Carpenter, MD
Phone: 734-936-4385
Email: eicarpen@umich.edu


Backup Contact:

N/A


Location Contact:

Ann Arbor, Michigan 48109
United States

Eilleen Carpenter, MD
Phone: 734-936-4385
Email: eicarpen@umich.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.